These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 25618219)

  • 21. High-throughput discovery of cancer-targeting TCRs.
    Bunse L; Green EW; Platten M
    Methods Enzymol; 2019; 629():401-417. PubMed ID: 31727251
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-affinity oligoclonal TCRs define effective adoptive T cell therapy targeting mutant KRAS-G12D.
    Sim MJW; Lu J; Spencer M; Hopkins F; Tran E; Rosenberg SA; Long EO; Sun PD
    Proc Natl Acad Sci U S A; 2020 Jun; 117(23):12826-12835. PubMed ID: 32461371
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cutting edge: inhibitory effects of CD4 and CD8 on T cell activation induced by high-affinity noncognate ligands.
    Chervin AS; Stone JD; Bowerman NA; Kranz DM
    J Immunol; 2009 Dec; 183(12):7639-43. PubMed ID: 19923452
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 4-1BB-based isolation and expansion of CD8+ T cells specific for self-tumor and non-self-tumor antigens for adoptive T-cell therapy.
    Choi BK; Lee SC; Lee MJ; Kim YH; Kim YW; Ryu KW; Lee JH; Shin SM; Lee SH; Suzuki S; Oh HS; Kim CH; Lee DG; Hwang SH; Yu EM; Lee IO; Kwon BS
    J Immunother; 2014 May; 37(4):225-36. PubMed ID: 24714356
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of human T-cell receptors with optimal affinity to cancer antigens using antigen-negative humanized mice.
    Obenaus M; Leitão C; Leisegang M; Chen X; Gavvovidis I; van der Bruggen P; Uckert W; Schendel DJ; Blankenstein T
    Nat Biotechnol; 2015 Apr; 33(4):402-7. PubMed ID: 25774714
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fab antibodies capable of blocking T cells by competitive binding have the identical specificity but a higher affinity to the MHC-peptide-complex than the T cell receptor.
    Neumann F; Sturm C; Hülsmeyer M; Dauth N; Guillaume P; Luescher IF; Pfreundschuh M; Held G
    Immunol Lett; 2009 Aug; 125(2):86-92. PubMed ID: 19524620
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular Pathways: Breaking the Epithelial Cancer Barrier for Chimeric Antigen Receptor and T-cell Receptor Gene Therapy.
    Hinrichs CS
    Clin Cancer Res; 2016 Apr; 22(7):1559-64. PubMed ID: 27037253
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor- and Neoantigen-Reactive T-cell Receptors Can Be Identified Based on Their Frequency in Fresh Tumor.
    Pasetto A; Gros A; Robbins PF; Deniger DC; Prickett TD; Matus-Nicodemos R; Douek DC; Howie B; Robins H; Parkhurst MR; Gartner J; Trebska-McGowan K; Crystal JS; Rosenberg SA
    Cancer Immunol Res; 2016 Sep; 4(9):734-43. PubMed ID: 27354337
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Degenerate recognition of T cell epitopes: impact of T cell receptor reserve and stability of peptide:MHC complexes.
    Ford ML; Evavold BD
    Mol Immunol; 2004 Feb; 40(14-15):1019-25. PubMed ID: 15036905
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ca2+ release from the endoplasmic reticulum of NY-ESO-1-specific T cells is modulated by the affinity of TCR and by the use of the CD8 coreceptor.
    Chen JL; Morgan AJ; Stewart-Jones G; Shepherd D; Bossi G; Wooldridge L; Hutchinson SL; Sewell AK; Griffiths GM; van der Merwe PA; Jones EY; Galione A; Cerundolo V
    J Immunol; 2010 Feb; 184(4):1829-1839. PubMed ID: 20053942
    [TBL] [Abstract][Full Text] [Related]  

  • 31. T cell receptor binding affinity governs the functional profile of cancer-specific CD8+ T cells.
    Tan MP; Gerry AB; Brewer JE; Melchiori L; Bridgeman JS; Bennett AD; Pumphrey NJ; Jakobsen BK; Price DA; Ladell K; Sewell AK
    Clin Exp Immunol; 2015 May; 180(2):255-70. PubMed ID: 25496365
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MHC multimer-guided and cell culture-independent isolation of functional T cell receptors from single cells facilitates TCR identification for immunotherapy.
    Dössinger G; Bunse M; Bet J; Albrecht J; Paszkiewicz PJ; Weißbrich B; Schiedewitz I; Henkel L; Schiemann M; Neuenhahn M; Uckert W; Busch DH
    PLoS One; 2013; 8(4):e61384. PubMed ID: 23637823
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structural bases for the affinity-driven selection of a public TCR against a dominant human cytomegalovirus epitope.
    Gras S; Saulquin X; Reiser JB; Debeaupuis E; Echasserieau K; Kissenpfennig A; Legoux F; Chouquet A; Le Gorrec M; Machillot P; Neveu B; Thielens N; Malissen B; Bonneville M; Housset D
    J Immunol; 2009 Jul; 183(1):430-7. PubMed ID: 19542454
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatitis C virus-cross-reactive TCR gene-modified T cells: a model for immunotherapy against diseases with genomic instability.
    Spear TT; Riley TP; Lyons GE; Callender GG; Roszkowski JJ; Wang Y; Simms PE; Scurti GM; Foley KC; Murray DC; Hellman LM; McMahan RH; Iwashima M; Garrett-Mayer E; Rosen HR; Baker BM; Nishimura MI
    J Leukoc Biol; 2016 Sep; 100(3):545-57. PubMed ID: 26921345
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expansion of Tumor-reactive T Cells From Patients With Pancreatic Cancer.
    Meng Q; Liu Z; Rangelova E; Poiret T; Ambati A; Rane L; Xie S; Verbeke C; Dodoo E; Del Chiaro M; Löhr M; Segersvärd R; Maeurer MJ
    J Immunother; 2016; 39(2):81-9. PubMed ID: 26849077
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of relationships between peptide/MHC structural features and naive T cell frequency in humans.
    Reiser JB; Legoux F; Gras S; Trudel E; Chouquet A; Léger A; Le Gorrec M; Machillot P; Bonneville M; Saulquin X; Housset D
    J Immunol; 2014 Dec; 193(12):5816-26. PubMed ID: 25392532
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells.
    Cameron BJ; Gerry AB; Dukes J; Harper JV; Kannan V; Bianchi FC; Grand F; Brewer JE; Gupta M; Plesa G; Bossi G; Vuidepot A; Powlesland AS; Legg A; Adams KJ; Bennett AD; Pumphrey NJ; Williams DD; Binder-Scholl G; Kulikovskaya I; Levine BL; Riley JL; Varela-Rohena A; Stadtmauer EA; Rapoport AP; Linette GP; June CH; Hassan NJ; Kalos M; Jakobsen BK
    Sci Transl Med; 2013 Aug; 5(197):197ra103. PubMed ID: 23926201
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A flexible docking approach for prediction of T cell receptor-peptide-MHC complexes.
    Pierce BG; Weng Z
    Protein Sci; 2013 Jan; 22(1):35-46. PubMed ID: 23109003
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function.
    Schmid DA; Irving MB; Posevitz V; Hebeisen M; Posevitz-Fejfar A; Sarria JC; Gomez-Eerland R; Thome M; Schumacher TN; Romero P; Speiser DE; Zoete V; Michielin O; Rufer N
    J Immunol; 2010 May; 184(9):4936-46. PubMed ID: 20351194
    [TBL] [Abstract][Full Text] [Related]  

  • 40. T-cell receptor binding affinities and kinetics: impact on T-cell activity and specificity.
    Stone JD; Chervin AS; Kranz DM
    Immunology; 2009 Feb; 126(2):165-76. PubMed ID: 19125887
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.